Company news

Gilead Sciences, Inc. news in 2023

Gilead Sciences, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Gilead Sciences to Present at Upcoming Invest...

May 1, 2023

Gilead Sciences Announces First Quarter 2023 Financial Results

April 26, 2023

Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023

April 12, 2023

Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities

March 21, 2023

Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

March 20, 2023

Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

March 19, 2023

Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV

February 21, 2023

Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies

February 20, 2023

Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023

February 13, 2023

U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer

February 2, 2023

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend

February 1, 2023

Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer

January 31, 2023

Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023

January 18, 2023

Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies

January 2, 2023

← Newer news releases

Calls in 2023

Decks in 2023